Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: This study examines whether the timing of botulinum toxin type A (BoNTA) treatments affects outcomes in patients with synkinesis, a sequela of Bell's Palsy characterized by disconjugate facial muscle movement.
Study Design: A retrospective chart review.
Setting: An urban academic medical center.
Methods: We reviewed the charts of synkinesis patients treated from 2016 to 2022. Data included procedural notes, intervention dates, and scores from the House-Brackmann (HB), Facial Clinimetric Evaluation (FaCE), Synkinesis Assessment Questionnaire (SAQ), and Facial Grading System (FGS).
Results: Sixty-seven patients (median age 54 years, average palsy duration 5.7 years) received BoNTA. Patients treated within 12 months (n = 28), 13 to 24 months (n = 12), and after 24 months (n = 23) showed no significant differences in changes to HB, FaCE, or SAQ scores. However, patients treated within 1 year had significantly higher FGS improvement (36.3) than the other groups (P = .03).
Conclusion: While FaCE, HB, and SAQ scores showed no significant differences, early BoNTA treatment within 1 year significantly improved FGS scores, indicating better outcomes. Therefore, early treatment is ideal for optimal response.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ohn.1205 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adoptive transfer of third-party donor CMV-specific T cells for refractory cytomegalovirus infection following umbilical cord blood transplantation.
Br J Haematol
September 2025
Department of Hematology, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Refractory cytomegalovirus (CMV) infection is a severe complication following umbilical cord blood transplantation (UCBT). Antiviral agents, the standard first-line therapy, are limited by toxicity and resistance without robust T-cell immunity. We evaluated third-party donor (TPD)-derived CMV-specific T cells (CMVSTs) as a treatment option.
View Article and Find Full Text PDFDupilumab monotherapy in super-elderly patients with bullous pemphigoid: a retrospective study on long-term efficacy and safety in mild to moderate cases.
J Dermatolog Treat
December 2025
Department of Dermatology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Background: Bullous pemphigoid (BP) is a common autoimmune subepidermal bullous disease. Dupilumab, an IL-4/IL-13 inhibitor, represents a novel therapeutic approach for BP, but real-world long-term data in super-elderly patients are limited.
Methods: This retrospective, single-center observational study included super-elderly BP patients (≥80 years) receiving dupilumab monotherapy from September 2022 to September 2024.
The cachexia index as a prognostic indicator in patients with cervical cancer treated with radiotherapy: A retrospective study.
Nutr Clin Pract
September 2025
Department of Clinical Nutrition, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Objective: The cachexia index (CXI) demonstrates potential as both a diagnostic tool for cachexia and a prognostic tool for survival in cancer. However, CXI's predictive value has not been verified in cervical cancer. The purpose of this study is to investigate the prognostic value of the CXI in patients with cervical cancer treated with radiotherapy.
View Article and Find Full Text PDFPulsed electromagnetic field stimulation therapy for Charcot foot ulcer: a randomized controlled trial.
Wounds
August 2025
Faculty of Physical Therapy, Cairo University, Cairo, Giza, Egypt.
Background: Charcot foot is a debilitating complication of peripheral neuropathy and is primarily associated with diabetes, leading to structural damage, ulceration, and osteomyelitis. Pulsed electromagnetic field (PEMF) therapy is a promising treatment modality for wound healing and bone metabolism.
Objective: To evaluate the efficacy of PEMF therapy in promoting bone growth and ulcer healing in patients with Charcot foot ulcers.
Accelerating patient transitions from hospital to home in the United Kingdom with single-use negative pressure wound therapy: a discharge pathway.
Wounds
August 2025
Solventum, Maplewood, MN, USA.
Background: Initially limited to inpatient use, negative pressure wound therapy (NPWT) is now frequently used in community settings. However, complexities in wound management step-down strategies in the United Kingdom, including regional variations in referral processes, lack of consensus on funding criteria, and limited availability of NPWT units, have led to extended hospital length of stay (LOS) for patients ready for discharge but still needing NPWT. Single-use NPWT (sNPWT) can serve as a bridge between hospital and community NPWT.
View Article and Find Full Text PDF